---
schema_version: "secwatch.filing_event.v1"
accession: "0001819790-23-000070"
form_type: "8-K"
ticker: "TARS"
cik: "0001819790"
company_name: "Tarsus Pharmaceuticals, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T18:52:14.877326+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Tarsus posts Q2 net loss $31.4M, gets FDA nod for XDEMVY, raises $100M

## Summary
- Net loss of $31.4M in Q2 2023 vs $5.7M loss in Q2 2022; no license revenue ($15.3M in prior year).
- Cash and marketable securities $178.2M at June 30, 2023; gross proceeds of $100M from August 2023 equity offering.
- FDA approved XDEMVY (lotilaner ophthalmic solution) 0.25% for Demodex blepharitis on July 24, 2023; launch expected end of August 2023.
- Completed enrollment of Galatea Phase 2a trial evaluating TP-04 for Rosacea; topline data expected in 1H 2024.
- Recruited 85-person sales force targeting ~15K optometrists/ophthalmologists; deployed by end of August.

## SEC filing metadata
- accession: 0001819790-23-000070
- form_type: 8-K
- ticker: TARS
- cik: 0001819790
- company_name: Tarsus Pharmaceuticals, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819790/000181979023000070/0001819790-23-000070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819790/000181979023000070/tars-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001819790-23-000070
- JSON: https://secwatch.observer/filing/0001819790-23-000070.json
- Plain text: https://secwatch.observer/filing/0001819790-23-000070.txt

## Key facts
- Earnings Releases
  Tarsus Pharmaceuticals, Inc. reported the second quarter ended June 30, 2023 results: net income net loss of $31.4 million.
  - Period: the second quarter ended June 30, 2023
  - Net income: net loss of $31.4 million
  - Result: reported results
  source text: Second quarter net loss for 2023 was $31.4 million, compared to a net loss of $5.7 million for the same period in 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819790/000181979023000070/0001819790-23-000070-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.